8-K: OS Therapies Secures $6 Million in Private Placement, Extends Cash Runway into 2026

OS Therapies has successfully closed a $6 million private placement, providing funding expected to last into 2026 and supporting the clinical development of their lead drug candidate.

Summary

• OS Therapies has closed a private placement financing, raising approximately $6 million before expenses.
• The funds will primarily support the clinical and regulatory milestones for OST-HER2, their lead therapeutic candidate, in recurrent, resected metastatic osteosarcoma.
• The company expects the funding to extend their operational runway into 2026.
• OS Therapies anticipates having the necessary clinical data and other requirements to seek FDA approval for commercialization of OST-HER2 by 2026.
• The company is eligible for a Priority Review Voucher (PRV) upon approval of OST-HER2, which they intend to sell.
• The most recent sale of a PRV was for $150 million, and the company believes the value of PRVs may increase.
• The private placement involved the sale of 1.5 million units at $4.00 per unit, each unit including preferred stock and a warrant.
• The preferred stock is convertible to common stock at $4.00, and the warrants have an exercise price of $4.40 per share.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a successful capital raise and a clear path to commercialization. The potential for a PRV sale adds significant upside. However, the risks associated with clinical trials and regulatory approvals temper the overall sentiment.

Positives

• The $6 million private placement provides necessary funding to continue operations into 2026.
• The company's eligibility for a Priority Review Voucher (PRV) represents a significant potential asset.
• The company is focused on a clear path to commercialization for OST-HER2.
• The company has received rare pediatric disease, fast track and orphan drug designations for OST-HER2 from the FDA.
• The company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2.

Negatives

• The private placement involved the issuance of preferred stock and warrants, which could dilute existing shareholders.
• The company is reliant on the successful approval of OST-HER2 by the FDA to realize the value of the PRV.
• The company is subject to restrictions on issuing additional shares of common stock for a period of time.

Risks

• The company's ability to achieve FDA approval for OST-HER2 is not guaranteed.
• The value of the PRV is subject to market conditions and regulatory changes.
• The company's financial projections are based on assumptions that may not materialize.
• The company is subject to risks and uncertainties described in their SEC filings.

Future Outlook

The company expects the capital raised to allow it to operate into 2026, by which time they believe they will have delivered the necessary clinical data and other requirements to be granted FDA authorization to begin commercialization of OST-HER2. The company also intends to sell the PRV it would earn upon receiving approval of OST-HER2.

Management Comments

• Paul Romness, MHP, Chairman & CEO of OS Therapies, stated that the company expects the capital raised in this financing to allow it to operate into 2026.
• Paul Romness also stated that the company believes it will have delivered the necessary clinical data and other Biologics License Authorization-enabling requirements to be granted authorization by the US Food & Drug Administration to begin commercialization of OST-HER2 for the prevention of recurrent, resected metastatic osteosarcoma in the United States.

Industry Context

The announcement is relevant to the biotechnology and pharmaceutical industries, particularly those focused on oncology and rare diseases. The potential sale of a PRV is a significant event in the rare disease space, as it provides a non-dilutive source of capital. The company's focus on osteosarcoma, a rare pediatric cancer, aligns with the industry's increasing attention to unmet medical needs.

Comparison to Industry Standards

• The $150 million valuation for a PRV is consistent with recent transactions, such as PTC Therapeutics' sale to Kebilidi.
• The maximum sale price of a PRV was in 2015 when AbbVie bought a priority review voucher from United Therapeutics for $350 million.
• The company's focus on antibody-drug conjugates (ADCs) and immunotherapies aligns with current trends in cancer treatment.
• The company's clinical trial for OST-HER2 is a Phase 2b trial, which is a standard stage for drug development before seeking regulatory approval.
• The company's approach of using Listeria bacteria to stimulate an immune response is a novel approach in the immunotherapy space.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees will benefit from the company's increased financial stability.
• Patients with osteosarcoma may benefit from the potential commercialization of OST-HER2.
• Investors in the private placement will have the opportunity to profit from the company's success.

Next Steps

• The company will use the proceeds from the private placement for working capital, primarily focused on the clinical and regulatory milestones to support commercialization of OST-HER2.
• The company will announce a data update from the OST-HER2 Phase 2b clinical trial during the week of the JP Morgan Healthcare Conference 2025.
• The company will file a registration statement with the SEC registering the resale of the shares of common stock underlying the securities issued in this private placement.
• The company will seek FDA approval for OST-HER2 in recurrent, resected metastatic osteosarcoma.
• The company intends to sell the PRV it would earn upon receiving approval of OST-HER2.

Key Dates

Keywords

Private Placement, OST-HER2, Priority Review Voucher, Osteosarcoma, Clinical Trial, FDA Approval, Biotechnology, Immunotherapy, ADC, Cancer